Last reviewed · How we verify
Anlotinib and TQB2450 solution
Anlotinib inhibits multiple receptor tyrosine kinases to block tumor angiogenesis and growth, while TQB2450 is a PD-L1 inhibitor that enhances anti-tumor immune response.
Anlotinib inhibits multiple receptor tyrosine kinases to block tumor angiogenesis and growth, while TQB2450 is a PD-L1 inhibitor that enhances anti-tumor immune response. Used for Non-small cell lung cancer, Other solid tumors (under investigation in Phase 3).
At a glance
| Generic name | Anlotinib and TQB2450 solution |
|---|---|
| Sponsor | Chinese PLA General Hospital |
| Drug class | Multi-target tyrosine kinase inhibitor + PD-L1 inhibitor combination |
| Target | VEGFR, FGFR, RET, c-KIT (anlotinib); PD-L1 (TQB2450) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
This combination targets both the tumor microenvironment and immune checkpoint pathways. Anlotinib is a multi-target tyrosine kinase inhibitor that blocks VEGFR, FGFR, and other kinases involved in angiogenesis and tumor proliferation. TQB2450 blocks the PD-L1/PD-1 interaction, releasing T-cell exhaustion and promoting anti-tumor immunity. The combination aims to synergistically reduce tumor growth through dual mechanisms.
Approved indications
- Non-small cell lung cancer
- Other solid tumors (under investigation in Phase 3)
Common side effects
- Hypertension
- Fatigue
- Diarrhea
- Immune-related adverse events
- Hand-foot skin reaction
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Anlotinib and TQB2450 solution CI brief — competitive landscape report
- Anlotinib and TQB2450 solution updates RSS · CI watch RSS
- Chinese PLA General Hospital portfolio CI